Chart Review for Potential Features of Myocarditis, Pericarditis, and Cardiomyopathy in Children and Adolescents Treated with Clozapine
Department of Child and Adolescent Psychiatry, Philipps-University of Marburg, Hans-Sachs-Strasse 4-8, 35033 Marburg, Germany.Journal of Child and Adolescent Psychopharmacology (Impact Factor: 2.93). 02/2004; 14(2):267-71. DOI: 10.1089/1044546041648977
Clozapine is known to cause cardiac side effects, including myocarditis, pericarditis, and cardiomyopathy. Prompted by a case of clozapine-related pericarditis in an adolescent, we undertook a retrospective chart review to discover whether any unrecognized cases of myocarditis, pericarditis, or cardiomyopathy were among the children, adolescents, and young adults we had treated with clozapine. The sample comprised a total of 36 patients, who were monitored regularly over a period ranging from 2.5 to 79 months. The average observation period was 7.5 months. Patients were assessed for potential indicators of myocarditis, pericarditis, or cardiomyopathy. In more than 66% of all patients, at least one of several parameters potentially indicative of pericarditis, myocarditis, or cardiomyopathy was abnormal in at least one instance during the observation period. In all cases in which abnormalities were discovered, the abnormalities were found to be unspecific for myocarditis, pericarditis, or cardiomyopathy. With the exception of the case which prompted our study, none of the patients were found to have developed any such disorder in the course of further treatment with clozapine.
Conference Paper: Fuzzy Logic Controller For A Seperately Excited D.C. MotorTENCON '91.1991 IEEE Region 10 International Conference on EC3-Energy, Computer, Communication and Control Systems; 09/1991
- [Show abstract] [Hide abstract]
ABSTRACT: Although second-generation antipsychotics (SGAs) are used increasingly in children and adolescents, data on the effectiveness and safety in pediatric populations are still sparse. Much of the safety information is derived from studies conducted in adults. This derivation is problematic because children and adolescents are exposed to SGAs during a phase of unparalleled physical and psychologic development that can affect pharmacokinetic and pharmacodynamic drug actions, efficacy, and side-effect patterns. This article presents an overview of SGA-related side effects in children and adolescents and strategies to monitor health outcomes effectively in youngsters receiving SGAs.Child and Adolescent Psychiatric Clinics of North America 02/2006; 15(1):177-206. DOI:10.1016/j.chc.2005.08.007 · 2.60 Impact Factor
- American Journal of Psychiatry 03/2006; 163(2):204-8. DOI:10.1176/appi.ajp.163.2.204 · 12.30 Impact Factor